1
项与 Allogeneic CTL therapy(Baylor College of Medicine) 相关的临床试验A Multicenter Pilot Study of Reduced Intensity Allogeneic Stem Cell Transplantation Followed by Adoptive Cellular Immunotherapy With Donor Derived Latent Membrane Protein (LMP) Specific-CTLs in Patients With Epstein-Barr Virus (EBV)Positive Refractory or Recurrent Hodgkin Lymphoma
The investigators intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP specific cytotoxic T-lymphocyte (CTL) infusions in EBV positive patients with poor risk Hodgkin Lymphoma. One of three reduced intensity conditioning regimens predetermined at each institutional center of the Childhood, Adolescent and Young Adult Lymphoma Cell Therapy Consortium (LCTC) will be utilized for related or matched unrelated adult donor allogeneic transplant followed by donor LMP specific CTL infusion for three doses post AlloSCT. The investigators hypothesize that the addition of donor derived LMP specific CTLs will be safe and feasible.
100 项与 Allogeneic CTL therapy(Baylor College of Medicine) 相关的临床结果
100 项与 Allogeneic CTL therapy(Baylor College of Medicine) 相关的转化医学
100 项与 Allogeneic CTL therapy(Baylor College of Medicine) 相关的专利(医药)
100 项与 Allogeneic CTL therapy(Baylor College of Medicine) 相关的药物交易